NEW YORK, Sept. 7, 2016 /PRNewswire/ -- Dipexium
Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical
company focused on the development and commercialization of
Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical
antimicrobial peptide, today announced that the European Patent
Office has issued a new Locilex patent in the European Union (EU).
The patent claims are directed to a novel formulation of Locilex,
a topical antimicrobial peptide formulated as a topical cream,
and the use of Locilex as a method of treating skin or wound
infections. The issued patent has an expiry date in June 2033.
"This constitutes the first patent granted by the European
Union, the second largest pharmaceuticals market in the world,"
stated David P. Luci, President
& Chief Executive Officer of Dipexium, "this is an important
building block for our commercialization strategy for Locilex in
Europe." Mr. Luci continued,
"Dipexium now has issued patents for Locilex in the US, EU, and
Japan, the three largest
pharmaceuticals markets in the world, as well as Australia and New Zealand. In addition,
Dipexium has obtained notice of allowance for patents in
Hong Kong and Korea. We anticipate
the issuance of additional patents for Locilex in other major
international markets throughout 2016 and 2017."
About Dipexium Pharmaceuticals, Inc.
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage
pharmaceutical company focused on the development and
commercialization of Locilex (pexiganan cream 0.8%), a novel,
broad-spectrum, topical antimicrobial peptide. Initially, Locilex
is targeted for the treatment of mild infections of diabetic foot
ulcers. Based on a compilation of available clinical and
microbiology data, Dipexium also considers Locilex to be a
promising product candidate to treat other mild and moderate skin
and skin structure infections, including infected decubitus ulcers,
infected burns, infected surgical wounds, infected animal bites,
and nasal colonization of methicillin-resistant staphylococcus
aureus (MRSA). For more information, visit
www.dipexiumpharmaceuticals.com.
Cautionary Note on Forward-Looking Statements
This press release and any statements of representatives and
partners of Dipexium Pharmaceuticals, Inc. (the "Company") related
thereto contain, or may contain, among other things, certain
"forward-looking statements" within the meaning of the U.S. federal
securities laws. Such forward-looking statements involve
significant risks and uncertainties. Such statements may
include, without limitation, statements with respect to the
Company's plans, objectives, projections, expectations and
intentions and other statements identified by words such as
"projects," "may," "will," "could," "would," "should," "believes,"
"expects," "anticipates," "estimates," "intends," "plans,"
"potential" or similar expressions. These statements are
based upon the current beliefs and expectations of the Company's
management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the
Securities and Exchange Commission and those that relate to the
Company's ability to leverage the expertise of employees and
partners to assist the Company in the execution of its
strategy. Actual results (including, without limitation, the
timing for and results of the clinical trials and proposed NDA
submission for Locilex®) may differ significantly from those set
forth in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company's control). The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
Company Contacts:
David P. Luci
President & Chief Executive Officer
Dipexium Pharmaceuticals, Inc.
212-269-2834
info@dipexium.com
David Garrett
Vice President, Finance & Corporate Development
Dipexium Pharmaceuticals, Inc.
212-269-2834
info@dipexium.com
© 2016 Dipexium Pharmaceuticals, Inc. All rights
reserved.